Officials are sounding the alarm after the Pediatric Brain Tumor Consortium was informed in August that it will no longer receive federal funding beyond March 2026.
The organization is composed of 15 academic centers and children’s hospitals located across the U.S., with the objective of rapidly conducting novel phase 1 and 2 clinical evaluations of new therapeutic agents, treatment delivery technologies and radiation treatment strategies in children from infancy to 21 years of age with primary central nervous system tumors.
